Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Montelukast API Companies

ID: MRFR/HC/6414-CR
94 Pages
Vikita Thakur
Last Updated: February 16, 2025
Several pharmaceutical companies were known to be involved in the production and distribution of Montelukast Active Pharmaceutical Ingredient (API), which is used in the manufacturing of medications for the treatment of asthma and seasonal allergies.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Montelukast API Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)10.8%
2024 Market Size$ 1.01 Billion
2025 Market Size$ 1.12 Billion
2035 Market Size$ 3.12 Billion
Key Players
Merck & Co.
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
Sandoz International GmbH
Aurobindo Pharma
Cipla Limited
Trends
  • Rising Demand for Respiratory Treatments
  • Advancements in Manufacturing Technologies
  • Focus on Sustainability
Opportunities
  • Rising Healthcare Expenditure
  • Regulatory Approvals and Guidelines
  • Increasing Prevalence of Asthma and Allergies
Summary Table of Contents Segmentation Methodology Download PDF

Top Industry Leaders in the Montelukast API Market

Montelukast API Key CompaniesLatest Montelukast Active Pharmaceutical Ingredient Companies Update
  • May 2023: Montelukast active pharmaceutical ingredient market leader Sandoz has announced a €25 million investment in its Holzkirchen, Germany, manufacturing facility to increase its biosimilar research capacities. By the fourth quarter of 2023, the business plans to have expanded its Biopharma Technical Development (BioTD) capabilities and converted the lab building into a cutting-edge biotech facility. The funding will be used to consolidate state-of-the-art labs and analytical resources into one convenient location. The funding "further solidifies Bavaria's standing as a prominent biotechnology powerhouse. Up to 45 full-time employees are likely to join the site as a result of capacity development and engagement with universities in Munich and research organizations, as stated by Sandoz.
  • July 2023: An estimated USD 90 million was disclosed by Sandoz, a world leader in generic and biosimilar pharmaceuticals including the Montelukast API. This investment would position Sandoz's Ljubljana facility as a significant hub for the company's research and development of biosimilar products. About two hundred new permanent employment will be created as a result of the relocation, and the company's capacity for developing biosimilars from start to finish will be bolstered by the move.  It also expands upon Sandoz's proven complete capabilities in Ljubljana for developing technologically challenging generic medications, particularly small molecule products.
  • May 2023: Sandoz, Novartis's generics subsidiary and a leader in off-patent generic and biosimilar drugs like Montelukast API, agreed to a multi-year strategic partnership with Just -Evotec Biologics, the Seattle, Washington, US subsidiary of Germany's Evotec, in May 2023. The deal includes the potential for the development and production of more biosimilars. It's the latest development in Sandoz's efforts to become an independent provider of off-patent pharmaceuticals.
List of Montelukast Active Pharmaceutical Ingredient Key companies in the market

  • Sandoz International GmbH (Germany)

  • Teva Pharmaceutical Industries Ltd (Israel)

  • Dr. Reddys Laboratories Ltd (India)

  • Morepen Laboratories Ltd (India)

  • Mylan N.V. (US)

  • Teva Pharmaceutical Industries Ltd (Israel)

  • Vintage Pharmaceuticals Inc (US)

  • Hikma Pharmaceuticals PLC (UK)

  • Glenmark (India)

  • Merck Sharp and Dohme Corp (US)

  • Sandoz International GmbH (Germany)

  • Hetero (India)

  • Aurobindo Pharma (India)

Related Reports

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035